Squamous cell carcinoma of the anal canal at the Queen Elizabeth Hospital: A local experience
Date
2007
Authors
Kichenadasse, G.
Zakaria, J.
Rodda, D.
Hewett, P.
Rieger, N.
Stephens, J.
Pittman, K.
Patterson, K.
Borg, M.
Price, T.
Editors
Advisors
Journal Title
Journal ISSN
Volume Title
Type:
Journal article
Citation
Asia Pacific Journal of Clinical Oncology, 2007; 3(4):214-218
Statement of Responsibility
Ganessan Kichenadasse, Jasiah Zakaria, David J Rodda, Peter J Hewett, Nicholas A Rieger, Jacqueline H Stephens, Ken Pittman, Kevin Patterson, Martin Borg, Timothy J Price
Conference Name
Abstract
Aim: Concurrent chemoradiotherapy is the standard treatment for squamous cell carcinoma of anal canal. We describe our experience of treating such patients at our center. Methods: Patients with anal squamous cell carcinoma were treated with a uniform sphincter preserving protocol at The Queen Elizabeth Hospital, South Australia. Standard radiotherapy along with 5-fluorouracil (750 mg/m² on days 1–5 and days 29–32) and mitomycin C (12 mg/m² on day 1 only) was given to eligible patients. Results: Of the 34 patients included in this study, nearly 60% were women. Most (89.3%) had T1-2 disease. One-third had nodal involvement. Twenty-seven had chemoradiotherapy, six had local excision alone and one had radiotherapy alone. Among those who had chemoradiation, 71.5% had a complete response and remained colostomy free until the last follow-up. Most completed the treatment without major side-effects. The 3 and 5-year disease free survival rate was 62% and 53%, respectively. All patients who failed chemoradiation underwent salvage surgery with a median survival time of 32.5 months. Conclusion: Sphincter preservation is the goal for anal cancers. Chemoradiotherapy is an important modality to achieve this goal.
School/Discipline
Dissertation Note
Provenance
Description
The definitive version is available at www.blackwell-synergy.com